



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/669,397	09/23/2003	Borzu Sohrab	LSI0090/US/2	1491
33072	7590	12/22/2006	EXAMINER	
KAGAN BINDER, PLLC SUITE 200, MAPLE ISLAND BUILDING 221 MAIN STREET NORTH STILLWATER, MN 55082			NATNITHITHADHA, NAVIN	
			ART UNIT	PAPER NUMBER
			3735	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		12/22/2006	PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

87

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/669,397	SOHRAB, BORZU	
	<b>Examiner</b>	<b>Art Unit</b>	
	Navin Natnithithadha	3735	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 01 December 2006.  
 2a) This action is **FINAL**.                    2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 42-51 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 42-51 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO/SB/08)  
     Paper No(s)/Mail Date 20061201.
- 4) Interview Summary (PTO-413)  
     Paper No(s)/Mail Date. \_\_\_\_\_.  
 5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_.

## DETAILED ACTION

### *Response to Amendment*

1. Claims 1-12, 14-4, and 52-66 have been cancelled. Claims 42-51 are pending.

### *Claim Rejections - 35 USC § 103*

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 42-49 and 51 are rejected under 35 U.S.C. 103(a) as being unpatentable by Uchigaki et al, US 6,830,551 B1 ("Uchigaki"), and further in view of Higgins et al, US 4,545,382 A ("Higgins").

Claim 42: Uchigaki teaches a method for "determining the concentration of at least one target constituent contained within biological fluid" (method of using a body fluid measuring apparatus for measuring the concentration of a specific component contained in body fluid such as glucose concentration in blood) (see col. 1, lines 6-10 and fig. 9), the method comprising the steps of:

providing "at least one micro-needle" (lancet) 52 comprising an "open distal end" (not labeled, see location of 52d) and a "lumen" (space) 52d;  
providing an "electrochemical cell" 52 within the lumen (the lancet is also the electrochemical cell), the cell comprising a "parallelly-spaced electrode configuration"

Art Unit: 3735

(tube 52a, which acts as an active electrode, and axial core 52b, which acts as a counterpart electrode, are parallelly-spaced apart, see fig. 9 and col. 13, lines 23-30) 52a/52b, wherein the electrode configuration 52a/52b is positioned at the open proximal end of the hollow micro-needle 52 (see fig. 9);

"inserting the open distal end of the micro-needle into the skin to a selected depth" (injures the skin with the lancet tip at the depth shown in fig. 9) (see col. 3, lines 31-36); and

"transferring a sample of at least one target constituent within the biological fluid present at the open distal end through the lumen and into the electrochemical cell" (blood along with glucose molecules is sucked into the fluid-sucking chamber by a capillary phenomenon) (see col. 3, lines 40-43).

In regards to the last two limitations "providing a first electrical signal to the electrochemical cell; and receiving a second electrical signal generated by the electrochemical cell, wherein the second electrical signal is representative of the concentration the constituent in the biological fluid," the Applicant states in paragraph [0066] of the Specification the following:

In the sensor systems of the present invention, the reference and working electrodes of the electrochemical cell are in electrical communication with a control means that sets the input reference signal transmitted to the electrochemical cell, receives the output signal from the electrochemical cell and then derives the concentration level of the analyte within the sample from the output signal. In other words the control means provides a means for applying an electrical current between the two electrodes, measuring a change in the current over time and relating the observed change in current to the concentration of analyte present in the electrochemical cell. The concentration of the analyte in the patient's blood is then derived, the numerical value of which is preferably provided as an output signal to a display means.

Art Unit: 3735

Uchigaki teaches applying a predetermined voltage to electrode 52a ("first electrical signal") to cause an anodal current in which the electronic circuit 24 measures the concentration of glucose in the blood sample on the basis of the current generated at electrode 52b ("second electrical signal") (see col. 10, line 66, to col. 11, line 7, and col. 13, lines 23-30). Thus, Uchigaki teaches the last two limitations in the claim based on the Applicant's disclosure.

Uchigaki does not teach the parallelly-spaced electrode configuration 52a/52b "substantially transverse" ("1. lying or extending across or in a cross direction; cross." *Dictionary.com Unabridged (v 1.0.1)*. Random House, Inc. 14 Dec. 2006. <[Dictionary.com http://dictionary.reference.com/browse/transverse](http://dictionary.reference.com/browse/transverse)>) to the micro-needle. However, Higgins teaches an electrochemical sensor electrode configuration 15, which measures glucose concentration, transverse to a micro-needle (hypodermic needle) 16 (see fig. 4). Furthermore, under a broad interpretation of "parallelly-spaced electrode configuration", Higgins' electrode configuration 15 is "parallelly spaced" with the skin of the user. Thus, it would have been obvious for one of ordinary skill in the art at the time the invention was made to modify Uchigaki's electrode configuration 52a/52b to be substantially transverse to the micron-needle because both Uchigaki and Higgins disclose inventions within the same field of art (in vivo glucose concentration determination).

Claims 43 and 44: Uchigaki teaches the selected depth for puncturing the skin with lancet 52 may be "smaller than the conventional apparatus" (see col. 14, lines 16-19) or

"pierce the skin to a smaller depth than is necessary" (see col. 5, lines 39-42). This depth would clearly be no greater than the "viable epidermis" or "stratum corneum."

Claim 45: Uchigaki teaches a "hydrophilic gel material" (a reactive layer containing a hydrophilic high polymer) 37/57 in contact with the electrochemical cell 52 and absorbs the biological fluid including glucose molecules (see col. 8, lines 2-19, col. 11, line 65 to col. 12, line 6, and fig. 9).

Claims 46 and 47: Uchigaki teaches a "control unit" (electronic circuit) in "electrical communication" with the electrochemical cell 52 and "deriving the concentration of the constituent in the patient's biological fluid from the second electrical signal" (calculates the value measured for the test material included in the blood glucose level on the basis of the current generated at the electrode) (see col. 13, lines 26-30).

Claim 48: Uchigaki teaches a display 22 for "displaying the concentration of the constituent in the patient's biological fluid from the second electrical signal" (the result of measurement is displayed) (see col. 11, lines 1-7).

Claim 49: Uchigaki teaches the electronic circuit 24 comprises a microcomputer and other components (see col. 10, lines 5-6), which would clearly include "software algorithm" to determine a measuring value such as the blood glucose level of the matter to be detected from the anode current (see col. 10, lines 6-8).

Claim 51: Uchigaki teaches the claimed limitation as maintaining the bodily fluid in the reactive layer 37 for 15 seconds and then applying the voltammetry for measurement (see col. 12, lines 8-21). This amount of time (15 seconds) is less the

Art Unit: 3735

amount of time (between 30 seconds to 5 minutes) needed to equilibrate a hydrophilic polymer layer as known in the art (see Kwon, US 6,207,400 B1, col. 6, lines 50-56).

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. Claim 50 is rejected under 35 U.S.C. 103(a) as being unpatentable by Uchigaki in view of Higgins, as applied to claim 42 above, and further in view of Kwon et al, US 6,207,400 B1.

Claim 50: As to claim 50, Uchigaki teaches the following (see col. 12, lines 8-21):

As the method for measurement, the state, in which the NaCl aqueous solution is sucked in the space 39, is maintained for 15 seconds and then cyclic voltammetry is applied. As conditions for measurement, a sweep rate was 100 mV/sec and a sweep range was 0 to 1000 mV. The results of the measurement will be shown in FIG. 7.

It is not clear as to whether Uchigaki discloses the step of maintaining the NaCl aqueous solution, which represents a body fluid sample, for 15 seconds in order to equilibrate the reactive layer 37. However, Kwon teaches the following (see col. 6, lines 50-56):

The gel may be applied to the target surface and sufficient time allowed for analyte form the target surface to equilibrate in the gel prior to the detection step. The time may be quite short such as from 30 seconds to 5 minutes. Detection may then be carried out by applying the sensing means to the gel such as by

Art Unit: 3735

contacting a membrane containing a suitable enzyme system for the analyte with the hydrogel.

Thus, it would have been obvious for one of ordinary skill in the art at the time the invention was made to modify Uchigaki to maintain the body fluid sample for 30 seconds to 5 minutes prior to measurement thus equilibrating the hydrophilic polymer layer 37/57 in order provide an accurate measurement.

***Conclusion***

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Navin Natnithithadha whose telephone number is (571) 272-4732. The examiner can normally be reached on Monday-Friday, 8:00-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Charles Marmor, II can be reached on (571) 272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Navin Natnithithadha  
Patent Examiner  
Art Unit 3735

NJ  
12/08/06